Introduction: Substance use disorder (SUD) may co-occur with psychiatric disorders, which can complicate assessment and care. Aim: To compare psychiatric morbidity among patients with SUD and non-substance users. Methods: An comparative cross-sectional study included 100 participants: 50 with SUD and 50 non-substance users. Sociodemographic and clinical information was collected, and psychiatric morbidity was assessed using a structured diagnostic interview. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Statistical significance was set at p<0.05. Results: Psychiatric morbidity was present in 33 participants with SUD (66.0%) and 14 non-substance users (28.0%; OR 4.99, 95% CI 2.13-11.69; p<0.001). In the SUD group, depressive disorder (24.0%) and anxiety disorder (20.0%) were the most frequent principal diagnoses. Among non-substance users, depressive disorder (10.0%) and anxiety disorder (8.0%) were most frequent. In the pooled analysis, psychiatric morbidity was associated with male sex, education of 10 years or less, and unmarried status. Associations with longer duration of substance use and multiple-substance use were not statistically significant. Conclusion: The results show a higher frequency of psychiatric morbidity among participants with SUD, particularly depressive and anxiety disorders. The findings require confirmation using actual study data and should not be interpreted as establishing causality.
Substance use disorder (SUD) is a significant health and social problem associated with impaired physical health, psychological well-being, relationships and everyday functioning. It involves a problematic pattern of substance use that causes clinically significant distress or impairment. Substance use may affect brain systems involved in reward, emotion, stress and self-control, while shared biological and social risk factors may contribute to both SUD and other psychiatric disorders.[1,2]
Psychiatric disorders such as depression, anxiety, psychosis and personality disorders can occur alongside SUD. This relationship may be complex and bidirectional: psychiatric symptoms may precede substance use, substance use may worsen existing symptoms, or symptoms may arise during intoxication or withdrawal. In a large community study, Regier et al. reported that 37% of people with an alcohol disorder and 53% of those with a drug disorder had a coexisting mental disorder.[3]
Indian studies also demonstrate the clinical relevance of this overlap. The National Mental Health Survey of India documented mental morbidity and substance use disorders across the country, while Subodh et al. identified a co-occurring psychiatric diagnosis in 32.4% of patients attending a tertiary-care de-addiction centre.[4,5] Coexisting psychiatric morbidity can complicate diagnosis, treatment adherence and recovery. Symptoms related to intoxication or withdrawal may also resemble independent psychiatric disorders, making careful clinical assessment important.
Comparing patients with SUD against people who do not use substances can help describe differences in the frequency and pattern of psychiatric morbidity in the study setting. Such information may support routine psychiatric assessment and coordinated care for substance-related and mental health conditions. Therefore, the present study compared psychiatric morbidity among patients with SUD and non-substance users.
AIM
To compare psychiatric morbidity in patients with substance use disorder and non-substance users.
OBJECTIVES
Source of Data
Data were obtained from adult participants attending the Psychiatry and De-addiction services. Participants with SUD were recruited from the Psychiatry outpatient department, inpatient services and/or de-addiction clinic.
Study Design
The study was conducted as a hospital-based, comparative cross-sectional study.
Study Location
The study was conducted in the Department of Psychiatry.
Study Duration
The study was carried out over 12 months.
Sample Size
The sample size was set at 100 participants: 50 patients with SUD and 50 non-substance users.
Inclusion Criteria
SUD group
Non-substance-user group
Exclusion Criteria
Procedure and Methodology
After ethics approval, potentially eligible participants were approached and screened against the eligibility criteria. The study purpose and procedures were explained, and written informed consent was obtained. Participants were enrolled consecutively until 50 eligible participants had been included in each group.
SUD status and substance-use history were assessed by a psychiatrist or trained study investigator using clinical evaluation and a structured diagnostic interview. Information recorded included the substance or substances used, duration and pattern of use, age at initiation, and relevant treatment history. Participants were interviewed when clinically stable; symptoms occurring during acute intoxication or withdrawal were not treated as an independent psychiatric diagnosis without clinical assessment.
Psychiatric morbidity was assessed in both groups using the Mini International Neuropsychiatric Interview (MINI). Diagnoses were assigned according to the diagnostic system adopted in the protocol. The same assessment procedure was used in both groups. Sociodemographic and clinical information was recorded on a structured proforma. Participant identifiers were replaced with study codes to maintain confidentiality.
Sample Processing
No biological sample processing was performed because the study assessed psychiatric diagnoses and clinical characteristics. Information from the interviews and records was coded, checked for completeness and entered into a password-protected electronic database for analysis.
Statistical Methods
Data were analysed using SPSS 28.0version. Categorical variables, including psychiatric diagnoses, sex and substance-use characteristics, were summarised as frequencies and percentages. Continuous variables, including age and duration of substance use, were summarised as mean and standard deviation or median and interquartile range, depending on their distribution. The chi-square test or Fisher’s exact test was used to compare categorical variables between groups. The independent-samples t test or Mann-Whitney U test was used for continuous variables, as appropriate. A two-sided p value below 0.05 was considered statistically significant.
Data Collection
Data were collected using a structured case-record form. The form included age, sex, education, occupation, marital status, residence, relevant medical and psychiatric history, and clinical details of substance use. Psychiatric diagnoses identified through the structured interview were recorded for both groups. Completed forms were reviewed for missing or inconsistent entries before data entry.
Table 1. Comparison of demographic characteristics and psychiatric morbidity between groups
|
Characteristic |
SUD group (n=50) |
Non-substance users (n=50) |
Test statistic |
Between-group estimate (95% CI) |
p value |
|
Age, years, mean (SD) |
38.6 (11.2) |
37.2 (10.8) |
t=0.64 |
Mean difference 1.40 years (−2.97 to 5.77) |
0.526 |
|
Male, n (%) |
42 (84.0) |
40 (80.0) |
χ²=0.27 |
OR 1.31 (0.47 to 3.66) |
0.603 |
|
Any psychiatric morbidity, n (%) |
33 (66.0) |
14 (28.0) |
χ²=14.49 |
OR 4.99 (2.13 to 11.69); risk difference 38.0 percentage points (18.7 to 53.2) |
<0.001 |
The mean age was 38.6 ± 11.2 years in the SUD group and 37.2 ± 10.8 years among non-substance users. This difference was not statistically significant (mean difference 1.40 years, 95% CI −2.97 to 5.77; t=0.64, p=0.526). Males comprised 84.0% of the SUD group and 80.0% of non-substance users, with no significant between-group difference (OR 1.31, 95% CI 0.47-3.66; χ²=0.27, p=0.603). Psychiatric morbidity was observed in 66.0% of participants with SUD compared with 28.0% of non-substance users. This difference was statistically significant (OR 4.99, 95% CI 2.13-11.69; risk difference 38.0 percentage points, 95% CI 18.7-53.2; χ²=14.49, p<0.001).
Table 2. Prevalence and pattern of psychiatric morbidity among patients with SUD
|
Principal diagnostic category |
n (%) of SUD group (N=50) |
95% CI for prevalence |
|
Any psychiatric morbidity |
33 (66.0) |
52.2-77.6% |
|
Depressive disorder |
12 (24.0) |
14.3-37.4% |
|
Anxiety disorder |
10 (20.0) |
11.2-33.0% |
|
Psychotic disorder |
5 (10.0) |
4.3-21.4% |
|
Personality disorder |
3 (6.0) |
2.1-16.2% |
|
Other psychiatric disorder |
3 (6.0) |
2.1-16.2% |
|
No psychiatric diagnosis |
17 (34.0) |
22.4-47.8% |
Among participants with SUD, 33 of 50 (66.0%; 95% CI 52.2-77.6%) had a psychiatric diagnosis, while 17 (34.0%; 95% CI 22.4-47.8%) had none. Depressive disorder was the most frequent principal diagnosis, recorded in 12 participants (24.0%; 95% CI 14.3-37.4%), followed by anxiety disorder in 10 (20.0%; 95% CI 11.2-33.0%). Psychotic disorder was recorded in 5 participants (10.0%), while personality disorder and other psychiatric disorders were each recorded in 3 (6.0%).
Table 3. Prevalence and pattern of psychiatric morbidity among non-substance users
|
Principal diagnostic category |
n (%) of non-substance users (N=50) |
95% CI for prevalence |
|
Any psychiatric morbidity |
14 (28.0) |
17.5-41.7% |
|
Depressive disorder |
5 (10.0) |
4.3-21.4% |
|
Anxiety disorder |
4 (8.0) |
3.2-18.8% |
|
Psychotic disorder |
2 (4.0) |
1.1-13.5% |
|
Personality disorder |
1 (2.0) |
0.4-10.5% |
|
Other psychiatric disorder |
2 (4.0) |
1.1-13.5% |
|
No psychiatric diagnosis |
36 (72.0) |
58.3-82.5% |
Among non-substance users, 14 of 50 participants (28.0%; 95% CI 17.5-41.7%) had a psychiatric diagnosis, and 36 (72.0%; 95% CI 58.3-82.5%) had none. Depressive disorder was the most frequent diagnosis, affecting 5 participants (10.0%; 95% CI 4.3-21.4%), followed by anxiety disorder in 4 (8.0%; 95% CI 3.2-18.8%). Psychotic disorder and other psychiatric disorders were each recorded in 2 participants (4.0%), while personality disorder was recorded in 1 (2.0%).
Table 4. Association of psychiatric morbidity with group, sociodemographic and selected clinical characteristics
|
Factor |
Category |
Psychiatric morbidity present, n/N (%) |
Test statistic |
OR (95% CI) |
p value |
|
Study group |
SUD |
33/50 (66.0) |
χ²=14.49 |
4.99 (2.13-11.69) |
<0.001 |
|
Non-substance users |
14/50 (28.0) |
Reference |
1.00 |
— |
|
|
Age |
≥40 years |
25/45 (55.6) |
χ²=2.40 |
1.88 (0.84-4.16) |
0.121 |
|
<40 years |
22/55 (40.0) |
Reference |
1.00 |
— |
|
|
Sex |
Male |
34/62 (54.8) |
χ²=4.02 |
2.34 (1.01-5.39) |
0.045 |
|
Female |
13/38 (34.2) |
Reference |
1.00 |
— |
|
|
Education |
≤10 years |
29/48 (60.4) |
χ²=6.67 |
2.88 (1.28-6.50) |
0.010 |
|
>10 years |
18/52 (34.6) |
Reference |
1.00 |
— |
|
|
Marital status |
Unmarried |
25/40 (62.5) |
χ²=6.43 |
2.88 (1.26-6.59) |
0.011 |
|
Married |
22/60 (36.7) |
Reference |
1.00 |
— |
|
|
Among participants with SUD only |
|||||
|
Duration of substance use |
>5 years |
19/24 (79.2) |
Fisher’s exact |
3.26 (0.93-11.38) |
0.078 |
|
≤5 years |
14/26 (53.8) |
Reference |
1.00 |
— |
|
|
Pattern of substance use |
Multiple substances |
15/18 (83.3) |
Fisher’s exact |
3.89 (0.94-16.13) |
0.067 |
|
Single substance |
18/32 (56.3) |
Reference |
1.00 |
— |
|
In the pooled sample, psychiatric morbidity was significantly more common among participants with SUD than among non-substance users (66.0% versus 28.0%; OR 4.99, 95% CI 2.13-11.69; p<0.001). Morbidity was also more frequent among males than females (54.8% versus 34.2%; OR 2.34, 95% CI 1.01-5.39; p=0.045), among participants with 10 or fewer years of education than those with more education (60.4% versus 34.6%; OR 2.88, 95% CI 1.28-6.50; p=0.010), and among unmarried than married participants (62.5% versus 36.7%; OR 2.88, 95% CI 1.26-6.59; p=0.011).
Table 1: Group characteristics and overall psychiatric morbidity
The two groups were similar in mean age: 38.6 years in the SUD group and 37.2 years among non-substance users. The difference was not statistically significant (p=0.526). The proportion of males was also comparable (84.0% versus 80.0%; p=0.603). This demographic similarity supports a straightforward descriptive comparison, although it does not control for other potential confounders. In Indian clinical samples, men often predominate among people seeking substance-use treatment; the eight-centre Indian dual-diagnosis study, for example, reported a 96% male sample [1]. The large National Mental Health Survey of India (NMHS) also found that mental morbidity varied by sociodemographic factors, including sex and education [2,3].
In the results, psychiatric morbidity was more frequent among participants with SUD than among non-substance users (66.0% versus 28.0%; OR 4.99, 95% CI 2.13-11.69; p<0.001). This pattern is consistent with the broader evidence that substance-use and psychiatric disorders frequently co-occur. A meta-analysis of epidemiological surveys reported elevated odds of depression and anxiety among people with substance-use disorders, while a later meta-analysis found a substantial association between mood disorders and substance-related disorders [4,5]. However, the prevalence of 66% is higher than some Indian clinical estimates. Subodh et al. reported dual diagnosis in 32.4% of patients at a North Indian de-addiction centre, and Ravikanth and Sultan reported psychiatric comorbidity in 33% of alcohol-dependent inpatients in rural South India [6,7].
The difference between estimates may reflect variation in the substances represented, whether tobacco-related disorders were counted, patient selection, diagnostic instruments, the distinction between current and lifetime diagnoses, and the timing of assessment relative to intoxication or withdrawal. Indian reviews have likewise described wide variation in reported psychiatric comorbidity across alcohol-use studies [8,9]. The example odds ratio indicates an association in the supplied table; it should not be interpreted as showing that SUD caused the psychiatric morbidity, or vice versa.
Table 2: Prevalence and pattern of morbidity in the SUD group
In the SUD group, 33 of 50 participants (66.0%) had a psychiatric diagnosis. Depressive disorder (24.0%) and anxiety disorder (20.0%) were the most frequent principal diagnoses, followed by psychotic disorder (10.0%). Personality and other psychiatric disorders each accounted for 6.0%.
The leading diagnoses resemble patterns described in Indian literature, although the exact proportions differ. Subodh et al. found affective disorders, anxiety disorders and psychotic disorders in 12.3%, 11.2% and 5.0% of de-addiction clinic attendees, respectively [6]. In Ravikanth and Sultan’s study of alcohol-dependent inpatients, mood disorders were most frequent, followed by anxiety and psychotic disorders [7]. A review of Indian alcohol-use research also notes that reported rates vary substantially across studies and diagnostic approaches [8].
The depression and anxiety proportions are within the broad ranges reported in Indian alcohol-use studies, but they are higher than those in some clinic-based samples. This could arise from differences in the diagnostic criteria, case mix, referral setting, inclusion of different substances and whether participants were assessed after a period of abstinence. International evidence also supports particular attention to mood and anxiety disorders: Lai et al. found increased odds of major depression and anxiety disorders among people with alcohol or illicit-drug-use disorders, and Saha et al. reported elevated pooled associations between mood and substance-related disorders [4,5].
The 10% prevalence of psychotic disorder is higher than the 5% reported by Subodh et al. and the 4% reported by Ravikanth and Sultan [6,7]. Differences in substance type and the assessment of substance-induced versus independent psychotic symptoms may contribute. Current practice guidance emphasises assessing psychiatric symptoms alongside substance history and clinical status, with collateral information and follow-up where appropriate [9,10]. Since these example categories are mutually exclusive principal diagnoses, they do not represent the full burden of possible multiple co-occurring diagnoses.
Table 3: Prevalence and pattern among non-substance users
In the comparison group, 28.0% had a psychiatric diagnosis. Depressive disorder was the most frequent category (10.0%), followed by anxiety disorder (8.0%); psychotic, personality and other disorders were less common. This estimate should be interpreted cautiously when compared with community prevalence surveys. The NMHS reported a current prevalence of any mental morbidity of 10.56%, while its estimate for common mental disorders was about 5.1% [2,3,11]. These surveys used population-based sampling, whereas the example comparison group is hospital-based and may have been selected through attendance at a health facility or a relationship to a patient. The diagnostic definitions and assessment instruments may also differ.
Consequently, the 28% prevalence should not be interpreted as the prevalence among all non-substance users in the community. It may reflect selection into the hospital sample, the criteria used to define “non-substance user,” or the method and timing of psychiatric assessment. The difference between the two groups is most informative when both were recruited from comparable settings and assessed using the same instrument and diagnostic rules.
Table 4: Sociodemographic and clinical associations
In the pooled analysis, psychiatric morbidity was more common among males, participants with 10 or fewer years of education and unmarried participants. The association with male sex was borderline (p=0.045), while education and marital status had stronger unadjusted associations. The NMHS reported higher overall mental morbidity among less-educated participants and males [2,3]. The Indian multicentre dual-diagnosis study also reported a predominantly male sample, though its design and selection criteria differ from those of this example [1]. These comparisons support examining social characteristics in clinical assessment, but the present table’s unadjusted estimates cannot establish that any one characteristic independently predicts morbidity.
Age group was not significantly associated with morbidity in the data (p=0.121). This result may reflect the small sample and the broad age categorisation at 40 years. It does not rule out age-related patterns in larger population studies. The NMHS described variation in mental morbidity across age groups, and national and international surveys have used more detailed age categories and adjusted analyses [2,3,12]. Differences in recruitment, age distribution and statistical power limit direct comparisons.
Among participants with SUD, psychiatric morbidity was numerically higher with substance-use duration greater than five years (79.2% versus 53.8%), but the association was not statistically significant (p=0.078). Indian findings on duration are mixed: Ravikanth and Sultan reported higher comorbidity with longer alcohol-use duration, while Subodh et al. did not find a consistent duration relationship [6,7]. A 2025 South Indian tertiary-centre study also described an association between longer substance-use duration and psychiatric comorbidity [13]. The wide confidence interval in the table indicates substantial uncertainty, so this trend should be treated as hypothesis-generating.
Morbidity was also numerically more frequent among participants reporting multiple substances than among those reporting a single substance (83.3% versus 56.3%), but this comparison was not statistically significant (p=0.067). Studies of people who inject drugs in India report substantial psychiatric comorbidity and concurrent substance use, though these selected populations are not directly comparable with a general SUD sample [14-16]. An observational study of people who inject opioids also described co-occurring psychiatric and psychosocial difficulties [17]. These findings make the pattern clinically plausible, but the small subgroup sizes and confidence interval crossing 1.0 mean that the data do not establish an association.
In this hospital-based comparison, psychiatric morbidity was more frequent among patients with substance use disorder (66.0%) than among non-substance users (28.0%). Depressive and anxiety disorders were the most frequently recorded diagnoses in both groups. Morbidity was also associated with male sex, lower educational attainment and unmarried status in the example data. Within the SUD group, the associations with longer substance-use duration and multiple-substance use did not reach statistical significance. These findings support assessing mental health alongside substance use in clinical care, while the cross-sectional design does not establish the direction or cause of the observed associations.
LIMITATIONS OF STUDY
The sample was small, hospital-based and potentially unrepresentative of people with SUD or non-substance users in the wider community. The cross-sectional design could not establish whether psychiatric disorders preceded substance use or developed alongside it. Substance-use histories and some clinical details may have been affected by recall or underreporting. Symptoms related to intoxication or withdrawal could also complicate psychiatric diagnosis. The small numbers in several diagnostic categories limited precision, as reflected in their wide confidence intervals. The reported associations were unadjusted and may have been influenced by confounding factors.